Biotech Profile
Kindling Bio – Creating One Scalable Gene Therapy to Flag Multiple Childhood Tumors for Immune Destruction
Founded just three months ago in August 2025, London-based Kindling Bio is inverting the standard adult-to-child drug translation model by developing a gene therapy platform designed specifically for childhood solid tumors from the outset. With £250k in launch funding and
31 October 2025